Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

xacin is a novel, broad spectrum, next-generation fluoroquinolone, that is more active than other quinolones against Gram-positive bacteria, including isolates of MRSA that are resistant to other quinolones. In large panel microbiological testing, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of less than or equal to 0.5 micrograms/mL for delafloxacin versus > 16 micrograms/mL for all other quinolones). Currently in development as an intravenous formulation, delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is interested in developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.(1)

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X is currently in Phase 2 tria
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... 2015  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... year ending December 31, 2014 after market close ... a conference call that day at 5:00 p.m. ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
Breaking Biology Technology:Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Wisconsin has some catching up to do even among ... investment, according to the latest Midwest Health Care Venture ... publicly disclosed investments in 12 states or regions in ... than three times the investment Wisconsin had. , ,These ...
... we continue to review biotech results for 2005 and try to ... , ,Another research tool I have always found useful for this ... the biotech industry. One of the things I like about Burrill ... the biotech industry's biggest cheerleaders. , ,Another aspect is that he ...
... The University of Wisconsin-Madison MBA program was ... and 19th among U.S. public university programs by the ... list in 2005. , ,These rankings are based on ... Financial Times compiled data provided by the schools and ...
Cached Biology Technology:2005 was a tough year for U.S. biotech financing 22005 was a tough year for U.S. biotech financing 32005 was a tough year for U.S. biotech financing 42005 was a tough year for U.S. biotech financing 5
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... A unique rover-based life detection system developed by Carnegie ... Chile's Atacama Desert, according to results being presented at ... in Houston. This marks the first time a rover-based ... this harsh region, which serves as a test bed ...
... chemical sensors that can be placed in the bloodstream ... (pH), or glucose levels is a major challenge for ... body responds to these foreign objects in ways that ... In the bloodstream, clots form on the surface of ...
... process by which a single gene can initiate production ... said Baylor College of Medicine researchers in a report ... Cell. "A major question in biology today is how ... proteins," said Dr. Bert O'Malley, chair of the BCM ...
Cached Biology News:Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 3Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 4Polymers with copper show promise for implanted sensors 2Polymers with copper show promise for implanted sensors 3Controlling protein diversity 2
Mouse anti human pro-Relaxin-2...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... to ErbB 2 - BSA and ... all tested applications). ... to KLH, corresponding to C terminal ... Entrez GeneID: ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: